A retrospective study of crizotinib in the treatment of patients with ALK-positive advanced non-small cell lung cancer (NSCLC) in real world setting

Trial Profile

A retrospective study of crizotinib in the treatment of patients with ALK-positive advanced non-small cell lung cancer (NSCLC) in real world setting

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Oct 2015

At a glance

  • Drugs Crizotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Oct 2015 New trial record
    • 06 Sep 2015 Results presented at the 16th World Conference on Lung Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top